In keeping with their role as leading innovators and experts on curcumin, Sabinsa’s scientific team has developed the next generation of curcuminoids. Potency, color, dosage, stability and bioavailability concerns are now addressed, which will only help increase curcumin’s popularity among researchers, manufacturers and consumers.

“For some time, curcuminoids have been poised to be the most widely used supplement based upon the range of real health benefits, as demonstrated by a robust body of science (much of which has been done on our Curcumin C3 Complex®). But this has been held back by several stumbling blocks,” said Sabinsa Marketing Director Shaheen Majeed. “The vivid color of curcumin is a manufacturing nightmare for many companies; our Curcumin C3 Reduct is a white powder. We were also able to increase dosage efficiency, meaning smaller capsules and tablets for consumers, while retaining greater potency, stability and much better bioavailability. This is the best thing to happen to curcumin since our original curcumin. It’s a game changer for the industry.”

Curcumin C3 Reduct, Sabinsa’s new patented and clinically safe 95% tetrahydrocurcuminoids, is the result of recent research into metabolites of curcuminoids that have unraveled the role of tetrahydrocurcuminoids as not only the major metabolites but also pharmacologically superior than curcuminoids themselves. It is not the curcumin, but its metabolite, tetrahydrocurcumin (THC), which is responsible for its biological function in the body.

Curcumin C3 Reduct, tetrahydrocurcuminoids (THCs), the cascading antioxidants and the major metabolites of Curcuminoids, are the colorless hydrogenated compounds derived from Sabinsa’s Curcumin C3 Complex® curcuminoids: curcumin, demethoxycurcumin and bisdemethoxycurcumin, of which curcumin is the main phenolic compound. As a cascading antioxidant, in comparison to a standalone antioxidant, Curcumin C3 Reduct will act as an antioxidant for a longer time and show cumulatively stronger activity.

With higher bioavailability in the gut compared to parent curcuminoids, tetrahydrocurcuminoids makes a better choice for oral supplementation. Curcumin C3 Reduct can be delivered in a smaller tablet or capsule. Sabinsa's recommended Curcumin C3 Complex dosage is 1500mg/daily, but new Curcumin C3 Reduct is recommended at 400mg/daily.

As a color-free extract with superior solubility and pH stability than curcuminoids, Curcumin C3 Reduct provides more formulation options to manufacturers.

Curcumin C3 Reduct has:

• Greater absorption

• Better antioxidant activity

• Better pharmacological activity

• Color-free

• Increased dosage efficiency

• Higher stability at physiological pH

Curcumin C3 Reduct is covered by these strictly enforced patents: US6653327, AU2006235807, EP1171144, EP1328263, NZ514884, US8119696, and JP2000-610495. It is Kosher and Halal certified, and allergen-free. More information can be found at www.sabinsa.com/products/faq/c3reduct.